NASH (Non-Alcoholic Steatohepatitis): When Fatty Liver Progresses to Liver Damage

Not all fatty livers are the same. For most people, fat accumulating in the liver is a quiet, stable condition that causes no immediate harm and can be reversed with lifestyle changes. But for a significant number of people, something more dangerous happens. The fat triggers the immune system. Inflammation ignites. Liver cells begin to die. Scar tissue forms. The liver, one of the body’s most essential and resilient organs, begins a slow descent toward irreversible damage. This is Non-Alcoholic Steatohepatitis — or NASH — and it is the moment when fatty liver disease crosses a critical line.

What Is NASH?

Nonalcoholic steatohepatitis, also called metabolic dysfunction-associated steatohepatitis or MASH, is an advanced form of nonalcoholic fatty liver disease. It arises from fat accumulation in the liver, triggering inflammation and liver cell damage. Fat deposition in NASH promotes swelling of the liver, which can lead to scarring over time. Ongoing scarring can eventually cause cirrhosis and, in some instances, liver failure. The Lancet

In 2023, global liver disease medical societies came together to rename the disease, with the goal of establishing a more accurate, non-stigmatising name. NASH was renamed Metabolic Dysfunction-Associated Steatohepatitis, or MASH. Despite this, NASH remains the term most widely recognised by patients and the public, so both terms are used in this article. PubMed

The key distinction between simple fatty liver and NASH is inflammation. In simple fatty liver, fat sits in the liver without causing active damage. In NASH, that fat triggers a destructive inflammatory response, injuring liver cells, causing them to balloon and die, and stimulating the production of scar tissue. MASH is a slowly progressive liver disease characterised by hepatic steatosis, inflammation, and fibrosis. Cleveland Clinic

How Common Is NASH?

NASH occurs in almost one-quarter of patients with NAFLD. It has an estimated prevalence of 1.5% to 6.45% in the general population. About 1.5% to 6.5% of US adults have MASH, with one estimate suggesting nine to fifteen million adults are affected. MASH prevalence is projected to increase by 63% by 2030. Pace HospitalAHA Journals

NASH is closely tied to the global rise in obesity and type 2 diabetes. NASH is associated with obesity and type 2 diabetes, hepatic complications including cirrhosis and hepatocellular carcinoma, and extrahepatic conditions including cardiovascular disease and cancer. What makes these statistics particularly alarming is that most people with NASH have no idea they have it — the liver produces no pain signals until the damage is already severe. Pace Hospital

How Does NASH Develop?

The progression from simple fatty liver to NASH involves multiple biological processes colliding in the liver simultaneously. Insulin resistance — the reduced ability of cells to respond to insulin — causes the liver to accumulate excess fat. Once fat builds beyond a certain level, it begins producing toxic byproducts that damage cell membranes and trigger oxidative stress. Overwhelmed fatty acid disposal mechanisms lead to lipotoxic species formation, triggering endoplasmic reticulum stress, oxidative stress, mitochondrial dysfunction, and inflammasome activation, ultimately driving the MASH phenotype characterised by hepatocellular injury, inflammation, and fibrosis. Medscape

The gut microbiome — the community of bacteria living in the intestines — also plays an important role. Dysbiosis of the gut microbiota compromises intestinal barrier integrity and increases permeability, facilitating the translocation of lipopolysaccharides and pro-inflammatory factors into the portal circulation, thereby promoting hepatic inflammation and injury. This explains why NASH is not simply a liver problem — it is a whole-body metabolic disorder that happens to express itself most catastrophically in the liver. Medscape

The Fibrosis Stages — From Damage to Cirrhosis

Once inflammation takes hold in the liver, the body attempts to repair the damage by laying down scar tissue — a process called fibrosis. NASH-related fibrosis is classified into five stages, from F0 (no fibrosis) through F1 and F2 (mild to moderate fibrosis) to F3 (bridging fibrosis, where scar tissue connects different parts of the liver) and finally F4 (cirrhosis, where the liver is extensively scarred and its normal architecture is destroyed).

Approximately 20% of patients with NASH progress to cirrhosis and are at high risk of developing hepatocellular carcinoma, with multiple factors driving this progression. Both simple steatosis and MASH are potentially reversible stages. However, if MASH progresses to cirrhosis, the histopathological changes become irreversible and may further lead to the development of hepatocellular carcinoma. Restart MedThe Lancet

In 2017, NASH was responsible for approximately 118,000 cirrhosis deaths globally, and an increasing proportion of patients are receiving liver transplantation for NASH in Europe and the United States. MASH has become one of the leading causes of adult liver transplantation among patients with hepatocellular carcinoma undergoing liver transplantation. Pace HospitalMedscape

Symptoms: The Dangerous Silence

One of the most serious challenges with NASH is that it progresses silently. MASH is not typically associated with symptoms. Some patients, however, may experience fatigue or pain in the upper right side of the abdomen, where the liver is located. AHA Journals

When symptoms do appear — persistent fatigue, abdominal discomfort, unexplained weight loss, or the yellowing of skin and eyes known as jaundice — they often indicate the disease has already reached an advanced stage. By the time someone feels unwell enough to seek medical attention, significant fibrosis may already be present. This is why identifying NASH in at-risk individuals — those with obesity, type 2 diabetes, or high cholesterol — through proactive screening is so important.

Beyond the liver itself, MASH increases the risk of heart attack, stroke, and other conditions affecting the heart. Cardiovascular disease is the leading cause of mortality in patients with MASLD, while those with severe liver fibrosis face an escalating risk of liver-related mortality. MedscapeThe Lancet

How Is NASH Diagnosed?

Diagnosing NASH involves several steps. A healthcare provider will take a physical examination and medical history, perform blood tests such as liver function tests measuring ALT and AST levels, and use imaging. Ultrasound, CT scan, or MRI can detect liver fat but cannot confirm inflammation or fibrosis. Elastography measures liver stiffness, helping identify fibrosis severity. The Lancet

Liver biopsy — the gold standard — remains the only test that can definitively confirm NASH by directly examining liver tissue under a microscope for the characteristic triad of fat, inflammation, and ballooning cell injury. However, biopsy carries a small risk of complications and is not performed routinely in all patients. Non-invasive scoring tools such as the FIB-4 index and APRI score, derived from standard blood tests, are increasingly used to estimate fibrosis risk and identify patients who need further investigation or liver biopsy.

For more information on liver health and global disease burden, visit the World Health Organization and ObserverVoice.com.

Treatment: Lifestyle First, Then the New Drug Era

The first line of treatment for MASH is weight loss through a combination of healthy eating, lower calorie intake, and increased physical activity. Weight loss of 3 to 5% may improve liver fat, while greater than 10% weight loss may improve fibrosis. Studies have demonstrated that moderate exercise — five times per week for a total of 150 minutes — may improve MASH outcomes. AHA Journals

Bariatric surgery showed MASH resolution in 56 to 70% of cases, though challenges remain regarding incomplete fibrosis reversal and the lack of long-term outcome data. For patients with severe obesity where lifestyle change alone has not been sufficient, bariatric surgery represents a powerful option. Cleveland Clinic

The field experienced a landmark moment in March 2024. With FDA approval of resmetirom, clinicians now have an evidence-based pharmacological option for treating adults with confirmed MASH and moderate to advanced fibrosis. Resmetirom demonstrated NASH resolution without worsening fibrosis in 26 to 30% of patients compared to 10% with placebo, and fibrosis improvement without worsening MASH in 24 to 26% of patients compared to 14% with placebo. Frontiers

Resmetirom works by selectively activating thyroid hormone receptors in the liver, reducing fat production and improving metabolic function specifically where the damage is occurring. GLP-1 receptor agonists — widely used for type 2 diabetes and obesity — are also showing considerable promise in NASH clinical trials and may soon expand the pharmacological toolkit available to patients and their doctors.

Frequently Asked Questions

Q1. What is the difference between NAFLD and NASH? NAFLD is the broader term for fat accumulation in the liver without significant alcohol use. NASH is the more serious subtype, where fat is accompanied by inflammation and liver cell damage. Think of NAFLD as the spectrum and NASH as the dangerous end of it. Not everyone with NAFLD develops NASH, but all NASH is part of the NAFLD spectrum.

Q2. Can NASH be reversed? Yes, in its earlier stages. NASH with fibrosis up to stage F3 is potentially reversible with significant weight loss, dietary improvement, and now with resmetirom. Once cirrhosis develops — stage F4 — the scarring is generally considered irreversible, though progression can be slowed. Early detection and intervention are crucial.

Q3. Does NASH always progress to cirrhosis? No. While approximately 20% of NASH patients develop cirrhosis over time, many people with NASH remain stable or even improve, particularly with lifestyle changes. The rate of progression depends on multiple factors including age, degree of obesity, presence of type 2 diabetes, genetic risk, and whether the inflammation is actively controlled.

Q4. Is NASH a risk factor for liver cancer? Yes. NASH-related cirrhosis significantly increases the risk of hepatocellular carcinoma — the most common form of liver cancer. Importantly, research shows liver cancer can sometimes develop in NASH patients even before cirrhosis is present, which is why regular surveillance is recommended for high-risk patients.

Q5. Who should be screened for NASH? Screening is particularly important for people with type 2 diabetes, obesity, metabolic syndrome, or significantly elevated liver enzymes on routine blood tests. A simple non-invasive fibrosis score such as FIB-4 is now recommended as a first-line screening tool in at-risk individuals, with further investigation for those with intermediate or high scores.

References

1. American Liver Foundation — Nonalcoholic Steatohepatitis (NASH): Symptoms and Complications
2. Cleveland Clinic — Metabolic Dysfunction-Associated Steatohepatitis (MASH)
3. PMC / NIH — Pathogenesis and Treatment of Non-alcoholic Steatohepatitis and Its Fibrosis
4. PMC / NIH — The Burden of Nonalcoholic Steatohepatitis: A Systematic Review
5. Frontiers in Nutrition — Global Burden of NASH-Related Liver Cancer
6. WHO — Hepatitis and Liver Disease

Disclaimer

This article adapts publicly available information from WHO’s Hepatitis page and other publicly available sources on non-alcoholic steatohepatitis, MASH, liver fibrosis, and metabolic liver disease. This content is for informational and educational purposes only and does not constitute medical advice. Diagnosis and management of NASH or MASH should always be guided by a qualified hepatologist, gastroenterologist, or healthcare professional. ObserverVoice.com is a news and information platform — not a healthcare provider.